These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37719477)

  • 1. Vitamin E and Pioglitazone: A Comprehensive Systematic Review of Their Efficacy in Non-alcoholic Fatty Liver Disease.
    Mazhar IJ; Yasir M; Sarfraz S; Shlaghya G; Narayana SH; Mushtaq U; Shaman Ameen B; Nie C; Nechi D; Penumetcha SS
    Cureus; 2023 Aug; 15(8):e43635. PubMed ID: 37719477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
    Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials.
    Gu Y; Sun L; He Y; Yang L; Deng C; Zhou R; Kong T; Zhang W; Chen Y; Li J; Shi J
    Expert Rev Gastroenterol Hepatol; 2023 Mar; 17(3):273-282. PubMed ID: 36689199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
    Blazina I; Selph S
    Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to pioglitazone in non-alcoholic fatty liver disease patients with
    Wang Z; Du H; Zhao Y; Ren Y; Ma C; Chen H; Li M; Tian J; Xue C; Long G; Xu M; Jiang Y
    Front Endocrinol (Lausanne); 2023; 14():1111430. PubMed ID: 37065735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
    Sanyal AJ; Williams SA; Lavine JE; Neuschwander-Tetri BA; Alexander L; Ostroff R; Biegel H; Kowdley KV; Chalasani N; Dasarathy S; Diehl AM; Loomba R; Hameed B; Behling C; Kleiner DE; Karpen SJ; Williams J; Jia Y; Yates KP; Tonascia J
    J Hepatol; 2023 Apr; 78(4):693-703. PubMed ID: 36528237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
    Musso G; Cassader M; Rosina F; Gambino R
    Diabetologia; 2012 Apr; 55(4):885-904. PubMed ID: 22278337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
    Musso G; Cassader M; Paschetta E; Gambino R
    JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis.
    Kovalic AJ
    J Clin Exp Hepatol; 2022; 12(4):1057-1068. PubMed ID: 35814516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin E and nonalcoholic fatty liver disease.
    Pacana T; Sanyal AJ
    Curr Opin Clin Nutr Metab Care; 2012 Nov; 15(6):641-8. PubMed ID: 23075940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
    Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J;
    Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.
    Gudan A; Jamioł-Milc D; Hawryłkowicz V; Skonieczna-Żydecka K; Stachowska E
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis.
    Komolafe O; Buzzetti E; Linden A; Best LM; Madden AM; Roberts D; Chase TJ; Fritche D; Freeman SC; Cooper NJ; Sutton AJ; Milne EJ; Wright K; Pavlov CS; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013157. PubMed ID: 34280304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
    Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.